123 related articles for article (PubMed ID: 28666315)
1. Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer.
Ciuffreda L; Del Curatolo A; Falcone I; Conciatori F; Bazzichetto C; Cognetti F; Corbo V; Scarpa A; Milella M
Ann Oncol; 2017 Nov; 28(11):2896-2898. PubMed ID: 28666315
[No Abstract] [Full Text] [Related]
2. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
3. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
Cirone P; Andresen CJ; Eswaraka JR; Lappin PB; Bagi CM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):525-38. PubMed ID: 24442130
[TBL] [Abstract][Full Text] [Related]
6.
Bush KT; Boichard A; Tsigelny IF
Anticancer Res; 2018 Apr; 38(4):1967-1977. PubMed ID: 29599312
[TBL] [Abstract][Full Text] [Related]
7. Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer.
Hong YB; Kim JS; Yi YW; Seong YS; Bae I
Pancreas; 2012 Apr; 41(3):496-8. PubMed ID: 22415672
[No Abstract] [Full Text] [Related]
8. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
9. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
[TBL] [Abstract][Full Text] [Related]
10. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Alagesan B; Contino G; Guimaraes AR; Corcoran RB; Deshpande V; Wojtkiewicz GR; Hezel AF; Wong KK; Loda M; Weissleder R; Benes CH; Engelman J; Bardeesy N
Clin Cancer Res; 2015 Jan; 21(2):396-404. PubMed ID: 25348516
[TBL] [Abstract][Full Text] [Related]
11. 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling.
Yue Y; Qian W; Li J; Wu S; Zhang M; Wu Z; Ma Q; Wang Z
Cancer Lett; 2020 Feb; 471():135-146. PubMed ID: 31811906
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.
Dumble M; Crouthamel MC; Zhang SY; Schaber M; Levy D; Robell K; Liu Q; Figueroa DJ; Minthorn EA; Seefeld MA; Rouse MB; Rabindran SK; Heerding DA; Kumar R
PLoS One; 2014; 9(6):e100880. PubMed ID: 24978597
[TBL] [Abstract][Full Text] [Related]
13. TAK-733, a Selective MEK Inhibitor, Enhances Voreloxin-induced Apoptosis in Myeloid Leukemia Cells.
Jasek-Gajda E; Gajda M; Jasińska M; Litwin JA; Lis GJ
Anticancer Res; 2018 Nov; 38(11):6147-6156. PubMed ID: 30396931
[TBL] [Abstract][Full Text] [Related]
14. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target.
Du X; He K; Huang Y; Xu Z; Kong M; Zhang J; Cao J; Teng L
Int J Oncol; 2020 Mar; 56(3):761-771. PubMed ID: 32124956
[TBL] [Abstract][Full Text] [Related]
16. A pharmacogenomic analysis using L1000CDS
Choi EA; Choi YS; Lee EJ; Singh SR; Kim SC; Chang S
Cancer Lett; 2019 Nov; 465():82-93. PubMed ID: 31404615
[TBL] [Abstract][Full Text] [Related]
17. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
19. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
20. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]